Shell Asset Management Co. Has $159,000 Stake in Neurocrine Biosciences, Inc. $NBIX

Shell Asset Management Co. lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 79.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,136 shares of the company’s stock after selling 4,486 shares during the quarter. Shell Asset Management Co.’s holdings in Neurocrine Biosciences were worth $159,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Assetmark Inc. boosted its stake in Neurocrine Biosciences by 10.8% in the 2nd quarter. Assetmark Inc. now owns 21,001 shares of the company’s stock valued at $2,640,000 after purchasing an additional 2,045 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Neurocrine Biosciences by 87.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 125,162 shares of the company’s stock worth $15,732,000 after buying an additional 58,562 shares in the last quarter. Saturn V Capital Management LP acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $7,313,000. Capital Fund Management S.A. boosted its position in shares of Neurocrine Biosciences by 15.9% in the second quarter. Capital Fund Management S.A. now owns 203,628 shares of the company’s stock valued at $25,594,000 after acquiring an additional 27,987 shares during the period. Finally, Rhenman & Partners Asset Management AB grew its stake in shares of Neurocrine Biosciences by 66.1% in the second quarter. Rhenman & Partners Asset Management AB now owns 149,217 shares of the company’s stock valued at $18,755,000 after acquiring an additional 59,400 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, Director Leslie V. Norwalk sold 1,190 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total transaction of $184,557.10. Following the sale, the director owned 6,239 shares in the company, valued at $967,606.51. The trade was a 16.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director George J. Morrow sold 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the transaction, the director owned 7,068 shares of the company’s stock, valued at $1,013,339.16. This represents a 67.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 61,966 shares of company stock worth $8,625,166. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Price Performance

NBIX stock opened at $130.10 on Friday. The stock has a market cap of $13.06 billion, a price-to-earnings ratio of 27.92, a P/E/G ratio of 0.67 and a beta of 0.31. The company has a 50 day simple moving average of $137.94 and a 200 day simple moving average of $140.27. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The company had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business’s quarterly revenue was up 28.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.69 EPS. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on NBIX. HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Royal Bank Of Canada lowered their target price on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a report on Thursday, February 12th. TD Cowen boosted their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. reduced their price target on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Wedbush raised their price objective on Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Sixteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $175.84.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.